JMKX007129 / Shanghai Jeyou Pharmaceutical - LARVOL DELTA

JMKX007129 is a next generation of androgen receptor inhibitor targeting N-terminal domain for the treatment of metastatic castration-resistant prostate cancers (AACR 2026) - "In summary, we have successfully developed JMKX007129, a novel small-molecule compound targeting the AR-NTD. Preclinical studies demonstrate that JMKX007129, both as a monotherapy and in combination with AR inhibitors or degraders, exhibits promising in vitro and in vivo efficacy and a favorable safety profile, indicating its potential to overcome resistance mediated by AR LBD mutations. IND-enabling studies for JMKX007129 are currently underway."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor